CVRx, Inc. (CVRX) News
Filter CVRX News Items
CVRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CVRX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CVRX News From Around the Web
Below are the latest news stories about CVRX INC that investors may wish to consider to help them evaluate CVRX as an investment opportunity.
Institutions own 39% of CVRx, Inc. (NASDAQ:CVRX) shares but private equity firms control 39% of the companyKey Insights Significant control over CVRx by private equity firms implies that the general public has more power to... |
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceMINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. |
Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales TeamMairs & Power, an investment advisor, released the “Mairs & Power Small Cap” third quarter 2024 investor letter. A copy of the letter can be downloaded here. Non-technology equities were the market leaders in the first quarter, but mega-cap technology companies made a strong comeback in the second quarter. The market expanded again in the most […] |
CVRx to Present at the Piper Sandler 36th Annual Healthcare ConferenceMINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. Ab |
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately $45,000 will continue in 2025, as published in the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. This follows the recent announcement that |
CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearShareholders will be ecstatic, with their stake up 30% over the past week following CVRx, Inc. 's ( NASDAQ:CVRX... |
CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising ExpensesCVRx Inc (CVRX) reports a 27% revenue increase in Q3 2024, but faces challenges with rising net loss and SG&A expenses. |
CVRx (CVRX) Reports Q3 Loss, Tops Revenue EstimatesCVRx (CVRX) delivered earnings and revenue surprises of -26.67% and 0.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
CVRx: Q3 Earnings SnapshotThe average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share. The medical device company posted revenue of $13.4 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $13.3 million. |
CVRx Reports Third Quarter 2024 Financial and Operating ResultsMINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the third quarter of 2024. Recent Highlights Total revenue for the third quarter 2024 was $13.4 million, an increase of 27% over the prior year quarterU.S. Heart Failure (HF) revenue |